Is Incyte Genomics Inc a growth stock? A data-driven read on its earnings momentum, price leadership, and demand, scored against every US stock from SEC filings and daily prices, and re-ranked after every close.
Yes, INCY fits the growth-stock profileAs of the 2026-07-27 close, INCY scores 84 out of 99 on our growth-stock rating, a strong growth-stock profile. That ranks it 117th of 4,897 rated US stocks, the top 2% of the market.
Its strongest trait is N (new highs & catalysts) at 98, and its weakest is S (supply & demand) at 47. INCY clears 4 of the six core growth traits we score per stock; the seventh, overall market direction, is judged market-wide.
On price, INCY carries a strong Relative Strength rating of 84, meaning it has outperformed about 84% of the market over the past year.
Underneath the score: quarterly earnings up 84% year over year, sales up 21%, trading at a fresh 52-week high, volume running 1.5× its 50-day average.
The six traits that separate real growth stocks from the rest: earnings, price leadership, and demand. Each is scored 1–99 against the whole US market. We compute them with the CANSLIM method, double-weighting earnings and relative strength.
| C | Current quarterly earnings most recent EPS growth vs. a year ago |
86 |
| A | Annual earnings growth multi-year earnings trend |
72 |
| N | New highs & catalysts proximity to new 52-week highs |
98 |
| S | Supply & demand volume behind the move vs. share supply |
47 |
| L | Leader or laggard Relative Strength within its group |
62 |
| I | Institutional sponsorship fund accumulation and 13F ownership |
59 |
INCY shows the earnings strength and price leadership that define a growth stock. That is what our screen flags, not a recommendation to buy. Timing and market direction still matter.
The stocks ranking above INCY today, the growth leaders you’d weigh against it.
Where INCY sits in its base, its 52-week path, and the trait trend over the past year.
Every US stock scored on the traits that define a growth stock and re-ranked after each close, with the top ranks, the full trait breakdown, and today’s market read.
Open the app, free through September 1Yes, INCY fits the growth-stock profile. INCY shows the earnings strength and price leadership that define a growth stock. That is what our screen flags, not a recommendation to buy. Timing and market direction still matter.
Incyte Genomics Inc (INCY) scores 84 out of 99 on our growth-stock rating as of the 2026-07-27 close, ranking 117th of 4,897 rated US stocks.
INCY's most recent quarterly earnings were up about 84% year over year, with sales up 21%.
INCY has a Relative Strength rating of 84, meaning it has outperformed roughly 84% of the US market over the trailing year.
Create a free Growth Stock Analyzer account to see where INCY ranks against every US stock, the stronger growth stocks to weigh against it, and its full price and earnings history.
Want the method behind the score? Read how we grade growth stocks with CANSLIM.